- Home
- EXEL vs VTRS Comparison
EXEL vs VTRS Comparison
Compare EXEL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- VTRS
- Stock Information
- Founded
- EXEL 1994
- VTRS 1961
- Country
- EXEL United States
- VTRS United States
- Employees
- EXEL N/A
- VTRS N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- EXEL Health Care
- VTRS Health Care
- Exchange
- EXEL Nasdaq
- VTRS Nasdaq
- Market Cap
- EXEL 9.8B
- VTRS 9.0B
- IPO Year
- EXEL 2000
- VTRS N/A
- Fundamental
- Price
- EXEL $36.17
- VTRS $8.77
- Analyst Decision
- EXEL Buy
- VTRS Hold
- Analyst Count
- EXEL 18
- VTRS 4
- Target Price
- EXEL $37.59
- VTRS $10.50
- AVG Volume (30 Days)
- EXEL 2.2M
- VTRS 13.4M
- Earning Date
- EXEL 05-13-2025
- VTRS 05-08-2025
- Dividend Yield
- EXEL N/A
- VTRS 5.41%
- EPS Growth
- EXEL 170.77
- VTRS N/A
- EPS
- EXEL 1.76
- VTRS N/A
- Revenue
- EXEL $2,168,701,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- EXEL $5.78
- VTRS N/A
- Revenue Next Year
- EXEL $10.94
- VTRS $1.20
- P/E Ratio
- EXEL $20.64
- VTRS N/A
- Revenue Growth
- EXEL 18.50
- VTRS N/A
- 52 Week Low
- EXEL $20.14
- VTRS $6.85
- 52 Week High
- EXEL $40.26
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- EXEL 43.89
- VTRS 57.48
- Support Level
- EXEL $34.90
- VTRS $8.47
- Resistance Level
- EXEL $40.26
- VTRS $9.57
- Average True Range (ATR)
- EXEL 1.21
- VTRS 0.30
- MACD
- EXEL -0.19
- VTRS 0.15
- Stochastic Oscillator
- EXEL 23.69
- VTRS 59.39
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.